Clinical Trial: Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence

U.S., May 7 -- ClinicalTrials.gov registry received information related to the study (NCT06958484) titled 'Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence' on April 21.

Brief Summary: Evaluation of the efficacy and safety of Iparomlimab and Tuvonralimab Injection (QL1706) in combination with bevacizumab for postoperative adjuvant treatment of HCC with high-risk recurrence risk

Study Start Date: May 01

Study Type: INTERVENTIONAL

Condition: HCC - Hepatocellular Carcinoma Adjuvant Treatment

Intervention: DRUG: Iparomlimab and Tuvonralimab Injection (QL1706) plus bevacizumab

The patients with high-risk recurrence w...